Cantor Fitzgerald initiated coverage on Ambrx Biopharma with a new price target

5/19/23 7:19:08 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Cantor Fitzgerald initiated coverage of Ambrx Biopharma with a rating of Overweight and set a new price target of $25.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AMAM

Date	Price Target	Rating	Analyst
9/25/2023	$15.00	Mkt Outperform	JMP Securities
9/12/2023	$26.00	Buy	BTIG Research
7/31/2023	$29.00	Outperform	RBC Capital Mkts
6/14/2023	$26.00	Buy	B. Riley Securities
6/2/2023	$30.00	Outperform	Oppenheimer
5/19/2023	$25.00	Overweight	Cantor Fitzgerald
4/7/2022	$16.00	Outperform	Robert W. Baird
2/28/2022	$6.00	Neutral	Goldman Sachs